ETHYL 2-(2,6-DIFLUOROANILINO)-2-OXOACETATE, 95.0%, 10g

5-Bromo-6-hydroxy-2-methylpyrimidin-4(1H)-one, 95.0%, 250mg

8-Chloroquinoline>98.0%(GC)25g

3-Amino-N,N-diethyl-4-(1-pyrrolidinyl)benzenesulfonamide, 97%, 250mg

(5-Bromo-2-methoxypyridin-4-yl)boronic acid, 95.0%, 250mg

5,7-DIFLUOROQUINOLINE-6-CARBOXYLIC ACID, 95.0%, 100mg

6-Bromo-2,4-dichloro-8-methoxyquinazoline, 95%, 1g

3,3-DIFLUORO-N-METHYLCYCLOBUTANAMINE HCL, 95.0%, 1g

N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-2-nitrobenzene-1,4-diamine, 97%, 1g

3-Fluoro-5-(trifluoromethyl)benzamide, 97.0%, 10g

TERT-BUTYL (1-(2-METHOXYETHYL)-4-OXO-4,5-DIHYDRO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)METHYLCARBAMATE, 95.0%, 250mg

Methyl 5-methylthiazole-2-carboxylate, 95.0%, 1g

GC capillary column ROTI®Cap-5 MS Ultra, 50 m, 0.20 mm, 0.20 µm, 1 Piece(s)